Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TTP Labtech Announces On-Going Growth

Published: Thursday, July 11, 2013
Last Updated: Thursday, July 11, 2013
Bookmark and Share
An investment of £3.8M in global R&D sees product sales grow over 20%.

TTP Labtech has reported details of its success in 2012, as well as its growth plans for 2013. Continuing its track record of pioneering automation drug discovery products, TTP Labtech’s £3.8M investment in R&D and entrance into new markets paid off as product sales for 2012 were up over 20 percent compared to the year previous, despite the challenging economy. This progress was driven by launching products into new markets, including biological sample storage and liquid handling for molecular biology applications, as well as continued growth in the sale of established products. 

“Many drug discovery laboratories are facing challenging circumstances that require them to continually optimise their screening strategies and harness more automation,” said Jas Sanghera, TTP Labtech’s Managing Director. “We’re poised to embrace these changes in the environment by driving the development of solutions that meet the ever-evolving needs of our customers and applying this insight to new market sectors.” 

As such, the company shifted emphasis slightly during 2012 to make more effective use of its considerable product development expertise, positioning it for strong growth this year. “When we started over a decade ago, we primarily provided consultative insight for customers requiring bespoke automated platforms,” commented Sanghera. “However, over the last few years, our internal R&D teams have proved time and time again to be exceptionally good at developing innovative new automated technologies that truly meet customer needs. In 2012, we continued to invest in our product development capabilities and see product sales as being a strong driver of revenue growth into 2013 and beyond.”

This approach has included optimising every department within the company to reflect the growing focus on the continual development of automated instrumentation for the life science industry. Importantly, TTP Labtech uses its consultative experience to help customers develop new applications and techniques, with customer needs forming a key driving force behind its R&D programs. 

“We trust the team at TTP Labtech implicitly, they always listen to us.” said Jose Quiroz of Dart NeuroScience LLC. “We have developed such good working relationships with them that we consider them friends – their engineering and support teams regularly visit us to follow-up on our progress. Their applications support has always been second to none.”  

Last year, the company introduced an automated -80°C biological sample management system for biobanking called arktic® and the dragonfly, a new liquid handler specifically developed for screen optimisation. Both have been enthusiastically welcomed by the market and are expected to perform well in 2013. The mirrorball® antibody discovery system, which was introduced in late 2011 and is the world’s first simultaneous multi-laser scanning system, is also rapidly gaining traction in the pharmaceutical and biotech sectors, and will start to significantly impact revenues during 2013. Furthermore, the new high content imager, acumen hci, is extremely well positioned to handle the high throughput imaging and analysis of complex cellular assays, which is now common place in the high content screening market. 

This year, the company will look to target the field of molecular biology. “Many of our products are well positioned to provide real value to customers carrying out analysis applications such as next generation sequencing (NGS) and qPCR by improving the efficiency and speed of sample preparation, as well as improving functional genomics studies, for example via automated RNAi screens,” said Sanghera. “With significant opportunities in this space and several other major product developments coming in 2013, these are exciting times for TTP Labtech.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

David Newble Joins TTP Labtech as New Managing Director
Recent appointment promises to drive innovation strategy and further strengthen R&D pipeline
Thursday, June 18, 2015
TTP Labtech and Almac Group’s Form Strategic Alliance
Alliance consolidates fluorescence lifetime technology to form a one-stop shop for compound screening.
Thursday, February 05, 2015
Innovative Technology Enables First Crystal Structure of mGlu5 Transmembrane Domain to be Determined
Several novel drug candidates have been identified to help treat specific neuropsychiatric disorders.
Saturday, July 19, 2014
TTP Labtech Revenues up 43%
The company has reported an impressive 43% increase in revenues and an associated increase in profits over 2013.
Monday, June 23, 2014
TTP Labtech Acquires Assets from AssayMetrics
Significant improvements in assay reagents and availability of HTS-compatible readers has propelled fluorescence lifetime technology to the vanguard of cost-effective screening technologies.
Thursday, January 09, 2014
Major Protein Structure Discovery Achieved Using TTP Labtech’s Mosquito LCP
Researchers have successfully reported the structure of a Class B G-Protein Coupled Receptor (GPCR) using lipidic cubic phase (LCP) protein crystallisation.
Friday, July 26, 2013
TTP Labtech Announces Company Growth
New product offering demonstrates strong commitment to product development.
Friday, May 11, 2012
Driving the Science of the Future
TTP LabTech announce that they are founding sponsors of the inaugural European Lab Automation (ELA) conference and exhibition, to be held at the Conference Centre Hamburg (CCH), Hamburg, Germany, from the 30th June-1st July.
Friday, May 20, 2011
Increased Demand Drives Queensland Compound Library Expansion
QCL capacity is increased by the acquisition of a fourth additional comPOUND® storage module.
Thursday, June 10, 2010
Improve your screening know-how with TTP LabTech at Screening Europe 2010
This year at Screening Europe 2010, TTP LabTech will be sharing its in-house expertise and technical advice with exhibition delegates in order to further improve current high content screening techniques and workflows.
Thursday, January 28, 2010
TTP LabTech Delivers Automated Chemistry System for Salt and Polymorph Screening to AstraZeneca
The three year laboratory automation project involved the design and build of a fully automated system for salt and polymorph screening of novel compounds.
Wednesday, January 28, 2009
TTP LabTech's European Roadshow
The roadshow offers the opportunity to try out the latest in low-volume liquid handling and high content screening systems, as well as learning more about compound management, instrumentation development and custom automation.
Thursday, September 13, 2007
TTP LabTech Announce US Expansion to Meet Growing Customer Demand
TTP LabTech further expands its US facilities with the recruitment of sales and customer service personnel for its East Coast office in Cambridge, MA.
Monday, July 30, 2007
TTP Extends Global Reach
After building up a strong base of customers in the USA and Europe over the past three years, TTP LabTech have now appointed distributors for Japan, India and Australia/New Zealand.
Wednesday, April 04, 2007
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!